dalteparin has been researched along with Leucocythaemia in 2 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chojnowski, K | 1 |
| Treliński, J | 1 |
| Wawrzyniak, E | 1 |
| Robak, T | 1 |
| Vignoli, A | 1 |
| Marchetti, M | 1 |
| Russo, L | 1 |
| Cantalino, E | 1 |
| Diani, E | 1 |
| Bonacina, G | 1 |
| Falanga, A | 1 |
1 trial available for dalteparin and Leucocythaemia
| Article | Year |
|---|---|
The influence of low molecular weight heparin on the intravascular activation of the coagulation system in patients with acute leukemia during induction chemotherapy--report of a prospective randomized study.
Topics: Acute Disease; Anticoagulants; Blood Coagulation; Disseminated Intravascular Coagulation; Humans; Le | 2002 |
1 other study available for dalteparin and Leucocythaemia
| Article | Year |
|---|---|
LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells.
Topics: Angiogenesis Inhibitors; Breast Neoplasms; Cell Line, Tumor; Endothelial Cells; Female; Fibroblast G | 2011 |